Skip to main content
OpenTrials
Completed

NCT Number: NCT02144532

Wearing a Compression Garment for Patients With Hypermobility Type of Ehlers-Danlos Syndrome

The Ehlers-Danlos syndrome (EDS) is a rare genetic disease caused by an anomaly of the connective tissue. This syndrome has different forms. Hypermobility type is the most common. It is characterized by generalized joint hypermobility, associated with a chronic pain syndrome. Pains appear as the most frequent demonstration of this syndrome, the worst lived and the most crippling.

Faced with insufficient effect of drug treatment, other alternatives have been proposed to relieve these patients. Compression garments have been developed. They appear as medical devices targeted specifically for patients with hypermobility EDS type: in the symptomatic treatment of joint pain, in stabilizing joints by proprioceptive effect and of muscle globulization, and in the functional improvement.

The VETCOSED study is a quasi-experimental study of type "Before / After", monocentric, open. The study is realized in the Centre Médico-Chirurgical et de Réadaptation des Massues - Croix Rouge Française de Lyon, in association with the Pôle Information Médicale Evaluation Recherche des Hospices Civils de Lyon. This study concerns about 40 patients with EDS hypermobility type, which will be followed for 8 weeks: 4 weeks during which they will wear a compression custom-made garment (short-sleeved vest CICATREX SED®), and 4 weeks during which they do not carry this garment.

The main objective is to demonstrate the effectiveness of compression garments in the EDS hypermobility type, especially in terms of symptomatic improvement joint pain.

The main outcomes expected of this study are:

* an improvement of the power and the peaks of couple of muscles rotators of shoulders. * a decrease of the pains and the defects of articular stability of the shoulder * an improvement of the quality of life and the functional independence of these patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ehlers-Danlos Syndrome Hypermobility Type Cardiovascular Diseases Collagen Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Connective Tissue Diseases Ehlers-Danlos Syndrome Ehlers-Danlos syndrome type 3 Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Skin Abnormalities Skin Diseases Skin Diseases, Genetic Skin and Connective Tissue Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Médecine Physique et de Réadaptation, Centre Médico-Chirurgical de Réadaptation des Massues - Croix-Rouge française

Lyon, 69322, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ehlers-Danlos syndrome hypermobility type confirmed the diagnosis of a geneticist
  • with an instability of one or both shoulders, painful or considered invalidating by the patient (recurrent dislocation or subluxation : at least once / month or at least 12 times / year)
  • having a joint hypermobility syndrome (abnormal mobility and in a non-physiological axis), with a Beighton score of greater than or equal to 5 of 9
  • age greater than or equal to 18 years
  • size greater than or equal to 1 m 40
  • sufficient understanding of the French language in order to respond to self-report questionnaires

Exclusion criteria

  • hyperalgic episode in progress
  • unstable cardiac disease
  • previous history of shoulder surgery
  • severe skin lesions,
  • pregnancy in progress

Treatment and study plan

short-sleeved vest CICATREX SED®)

Device

Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).

Primary outcomes

  1. Power (in watts) of the external rotators of the shoulder of the dominant arm measured by concentric isokinetic evaluation at a constant angular velocity of 180 °/s

    Time frame: 2 months follow-up

    The evaluations will be conducted 3 times:

    • at the inclusion (D0)
    • at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28)
    • at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56) For each measurement, evaluations will be made with then without the compression garment.

Secondary outcomes

  1. Level of pain expressed in the shoulders of patients

    Time frame: D0,D28,D56

    Evaluation of the level of pain each month by the physician investigator on Visual Analogue Scale :

    • at the inclusion (D0)
    • at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28)
    • at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56)

  2. Score of quality of life measured by the medical outcomes study Short-Form General Health Survey (SF-36 scale)

    Time frame: D0,D28,D56

    The score of quality of life is measured by self-administered questionnaire (SF-36 scale) at each follow-up visit:

    • at the inclusion (D0)
    • at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28)
    • at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56)

  3. Score of satisfaction measured by the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)

    Time frame: D0,D28,D56

    The score of satisfaction is measured by self-administered questionnaire (QUEST) at each follow-up visit:

    • at the inclusion (D0)
    • at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28)
    • at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56)

  4. Functional independence score measured by Health Assessment Questionnaire (HAQ)

    Time frame: D0,D28,D56

    The score of functional independence is measured by self-administered questionnaire (HAQ) at each follow-up visit:

    • at the inclusion (D0)
    • at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28)
    • at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56)

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Effectiveness of Wearing a Compression Garment (SED CICATREX® Model) for Patients With Hypermobility Type of Ehlers-Danlos Syndrome

Acronym: VETCOSED

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
May 22, 2014
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.